-

$undefined

N/A

(N/A)

Dogwood Therapeutics NasdaqCM:DWTX Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include Halneuron, which is in late-stage clinical development for the treatment of chemotherapy-induced neuropathic pain; IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia; and IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is headquartered in Alpharetta, Georgia.

Location: 44 Milton Avenue, Alpharetta, GA, 30009, United States | Website: https://www.dwtx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

69.93M

Cash

14.85M

Avg Qtr Burn

N/A

Short % of Float

13.46%

Insider Ownership

14.98%

Institutional Own.

7.95%

Qtr Updated

03/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IMC-1 (famciclovir + celecoxib) Details Fibromyalgia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Halneuron Details Chemotherapy-induced neuropathic pain	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-2 (valacyclovir and celecoxib) Details Long COVID-19	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.